Investor Overview

Company Profile

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat neurological and kidney diseases. 

Our lead compound, DM199, is currently in a Phase II clinical trial for acute ischemic stroke with plans to initiate clinical trials in patients with chronic kidney disease. To date, we have completed 5 clinical trials in over 130 patients. 

-

Stock Snapshot

DMAC Symbol
Nasdaq Market
-- Volume
-- Price
-- Change
DMA Symbol
TSXV Market
-- Volume
-- Price
-- Change
Go to Detailed Stock Information ›